| 000 | 01855 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517202908.0 | ||
| 264 | 0 | _c20181023 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1473-5687 | ||
| 024 | 7 |
_a10.1097/MEG.0000000000001101 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPyrsopoulos, Nikolaos | |
| 245 | 0 | 0 |
_aThe safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. _h[electronic resource] |
| 260 |
_bEuropean journal of gastroenterology & hepatology _c07 2018 |
||
| 300 |
_a761-765 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 |
_aBenzimidazoles _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorenes _xadverse effects |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis C _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aLiver Cirrhosis _xdiagnosis |
| 650 | 0 | 4 |
_aLiver Transplantation _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRibavirin _xadverse effects |
| 650 | 0 | 4 | _aSofosbuvir |
| 650 | 0 | 4 | _aSustained Virologic Response |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUridine Monophosphate _xadverse effects |
| 650 | 0 | 4 |
_aVirus Activation _xdrug effects |
| 700 | 1 | _aTrilianos, Panagiotis | |
| 700 | 1 | _aLingiah, Vivek A | |
| 700 | 1 | _aFung, Phoenix | |
| 700 | 1 | _aPunnoose, Merlin | |
| 773 | 0 |
_tEuropean journal of gastroenterology & hepatology _gvol. 30 _gno. 7 _gp. 761-765 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MEG.0000000000001101 _zAvailable from publisher's website |
| 999 |
_c28123051 _d28123051 |
||